The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process

被引:104
作者
Jones, T. Hugh [3 ,4 ]
Saad, Farid [1 ,2 ]
机构
[1] Bayer Schering Pharma, Sci Affairs Mens Healthcare, Berlin, Germany
[2] Gulf Med Univ, Sch Med, Ajman, U Arab Emirates
[3] Barnsley Hosp NHS Fdn Trust, Ctr Diabet & Endocrinol, Barnsley, England
[4] Univ Sheffield, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England
关键词
Testosterone; Atherosclerosis; Cardiovascular; CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; HORMONE-BINDING-GLOBULIN; ENDOGENOUS SEX-HORMONES; BODY-FAT DISTRIBUTION; ENDOTHELIAL PROGENITOR CELLS; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; ANDROGEN DEPRIVATION THERAPY; PLACEBO-CONTROLLED TRIAL; MIDDLE-AGED MEN;
D O I
10.1016/j.atherosclerosis.2009.04.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is becoming increasingly evident that the low serum levels of testosterone experienced by aging men are associated with increased all-cause mortality from CHD and other vascular disorders. Achieving a normal physiological testosterone concentration through the administration of testosterone therapy has been shown to provide beneficial effects on the pathophysiological markers and clinical symptoms of CHD. Many of the factors involved in the atherosclerotic process are interlinked with other, increasingly prevalent pathological conditions such as obesity, the metabolic syndrome (MetS), type 2 diabetes and erectile dysfunction, suggesting that testosterone therapy has potentially wide-ranging health benefits. As the number and scope of testosterone substitution and androgen deprivation studies increases and evidence accumulates, it is timely to assess available data and this review summarises the current understanding of the effects of testosterone on cardiovascular risk factors with particular emphasis on the relevance of testosterone treatment. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:318 / 327
页数:10
相关论文
共 192 条
[1]   Sex steroid hormones, upper body obesity, and insulin resistance [J].
Abate, N ;
Haffner, SM ;
Garg, A ;
Peshock, RM ;
Grundy, SM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10) :4522-4527
[2]   Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome [J].
Adiels, Martin ;
Olofsson, Sven-Olof ;
Taskinen, Marja-Riitta ;
Boren, Jan .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (07) :1225-1236
[3]  
AGLEDAHL I, 2008, SCAND J CLIN LAB INV, V11, P1
[4]  
Alexandersen P, 1999, CIRC RES, V84, P813
[5]   Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men [J].
Allan, C. A. ;
Strauss, B. J. G. ;
Burger, H. G. ;
Forbes, E. A. ;
McLachlan, R. I. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (01) :139-146
[6]   Androgen supplementation in eugonadal men with osteoporosis - Effects of 6 months of treatment on bone mineral density and cardiovascular risk factors [J].
Anderson, FH ;
Francis, RM ;
Faulkner, K .
BONE, 1996, 18 (02) :171-177
[7]   METABOLIC AND BEHAVIORAL-EFFECTS OF HIGH-DOSE, EXOGENOUS TESTOSTERONE IN HEALTHY-MEN [J].
BAGATELL, CJ ;
HEIMAN, JR ;
MATSUMOTO, AM ;
RIVIER, JE ;
BREMNER, WJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (02) :561-567
[8]   ENDOGENOUS SEX-HORMONES AND CARDIOVASCULAR-DISEASE IN MEN - A PROSPECTIVE POPULATION-BASED STUDY [J].
BARRETTCONNOR, E ;
KHAW, KT .
CIRCULATION, 1988, 78 (03) :539-545
[10]   Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males [J].
Barud, W ;
Palusinski, R ;
Beltowski, J ;
Wójcicka, G .
ATHEROSCLEROSIS, 2002, 164 (02) :283-288